Article
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Hepatology (Baltimore, Md.) - 1 Jun 2018
Foster Graham R, Agarwal Kosh, Cramp Matthew E, Moreea Sulleman, Barclay Stephen, Collier Jane, Brown Ashley S, Ryder Stephen D, Ustianowski Andrew, Forton Daniel M, Fox Ray, Gordon Fiona, Rosenberg William M, Mutimer David J, Du Jiejun, Gilbert Christopher L, Asante-Appiah Ernest, Wahl Janice, Robertson Michael N, Barr Eliav, Haber Barbara
Abstract excerpt
Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis. The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants with GT3 infection. This was a phase 2, randomized, open-label study. Treatment-naive participants...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.